Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors. (2020). SKIN The Journal of Cutaneous Medicine, 4(6), s108. https://doi.org/10.25251/skin.4.supp.108